What AMIC offers that microfracture alone does not

For many patients with a focal hip cartilage lesion, the conversation with a surgeon eventually reaches microfracture — a technique that drills small channels into the bone beneath the damaged cartilage to release stem cells. On its own, microfracture produces a repair tissue that is structurally weaker than native cartilage and, in published series, tends to degrade within two to three years. It can also leave the subchondral bone plate in a state that makes future repair procedures more difficult.

AMIC (Autologous Matrix-Induced Chondrogenesis) addresses both of those limitations in a single operation. After the microfracture step, a biocompatible collagen scaffold is fixed over the treated area to stabilise the healing environment and guide cell development into more durable cartilage-like tissue. No biopsy appointment, no cell-culture laboratory phase, and no return visit for a second operation are required — unlike two-stage alternatives such as ACI or MACI.

Within the broader hip care pathway — which runs from symptom management and injection support through to cartilage restoration and, ultimately, joint replacement — AMIC sits firmly at the cartilage-restoration stage. Its primary aim is to preserve the native hip joint and reduce the likelihood of early replacement, particularly in patients under 50 with a contained focal defect.

How the procedure works

The operation is performed arthroscopically, through small incisions, with three steps carried out in sequence during the same surgical session.

First, unstable and damaged cartilage is removed from the lesion down to the firm bone beneath, creating a clean-edged defect ready to receive repair tissue.

Second, small channels — typically spaced one to two millimetres apart — are drilled into the exposed bone surface. This is the microfracture stage: it opens the bone's inner layer so that bone marrow cells, including mesenchymal stem cells (the body's own tissue-building cells), rise up and fill the prepared space, forming a clot.

Third, a bilayer collagen membrane — Chondro-Gide® (Geistlich Pharma AG) — is trimmed to the exact shape of the defect and fixed in place with fibrin glue. The membrane does three things simultaneously: it seals the clot against disruption by the joint's synovial fluid, holds the stem cells in close contact with the bone surface, and provides a physical scaffold along which those cells begin to produce cartilage-like repair tissue. Over the following months, the membrane is naturally resorbed — it does not remain as a permanent implant.

Where femoroacetabular impingement or a torn labrum has contributed to the cartilage damage, correcting those problems at the same sitting is standard practice, addressing the mechanical cause alongside the lesion itself.

What the evidence shows

A 2025 PRISMA-compliant meta-analysis pooling 628 hips across 12 studies recorded a success rate of 99.6% and a mean improvement of 35.8 points in the modified Harris Hip Score — the standard functional measure for hip outcomes — with every patient-reported outcome measure reaching statistical significance after surgery.

The figure that may matter most to younger patients is joint preservation. A 2024 systematic review of 209 hips found zero conversions to total hip replacement in AMIC-treated groups, compared with conversion rates of up to 32.6% in microfracture-alone control groups at the same centres. The largest single published series — 201 patients followed for five years — recorded a 39.1-point mHHS improvement sustained throughout that period, with scores peaking at three years.

Imaging adds a structural layer to these findings. Mid-term MRI assessment using the MOCART score produced a mean of 67.5, indicating reasonable defect fill and tissue integration, though some patients showed subchondral bone changes on longer-term scanning — a real limitation that consultant assessment should address when reviewing individual cases.

The principal evidence gap is long-term randomised controlled trial data specific to the hip. The UK REPAIR pilot trial (IRAS 326268, sponsored by Northumbria Healthcare NHS Foundation Trust) is directly comparing AMIC against microfracture alone for acetabular defects and will add NHS-level evidence once results are available. That trial remains ongoing.

Who is a suitable candidate

AMIC works within a fairly well-defined patient profile, and understanding where that boundary lies is the first step for any patient considering a referral — or any GP and physiotherapist making one.

Age and joint health

Published trials consistently enrol patients aged 18 to 50, with some protocols extending to 55. The weighted mean age across available studies is approximately 36 years. Age itself acts as a proxy for joint biology: younger joints respond more reliably to repair, partly because the surrounding cartilage environment is better preserved.

Lesion type and size

AMIC targets focal, full-thickness defects — areas where cartilage has worn completely through to bone — corresponding to Outerbridge or ICRS Grade III–IV. Published series typically describe lesions in the range of 2–5 cm², but the upper size threshold is not rigidly defined; lesion position, hip anatomy, and individual clinical assessment all influence what is technically achievable in each case.

Background osteoarthritis

The Tönnis classification grades background joint wear from plain X-rays. Tönnis grade 0 or 1 — little or no joint-space narrowing — represents the usual threshold for cartilage repair. At grade 2 or above, the existing joint damage is too widespread for repair tissue to take hold effectively; the evidence does not support AMIC in that setting.

Underlying cause

Femoroacetabular impingement (FAI) is the most common source of the focal lesions that qualify for AMIC. Where impingement is identified, correcting it at the same operation is standard practice; leaving it unaddressed places any repaired cartilage at ongoing mechanical risk.

Patients who fall outside this window — older, with diffuse osteoarthritis, or Tönnis grade ≥2 — are more appropriately guided toward a hip replacement discussion, which remains a well-evidenced pathway in its own right.

Recovery after AMIC hip surgery

Planning around a recovery takes more than knowing when you might return to the gym — most patients need to arrange help at home, time off work, and childcare support before they commit to any operation. The AMIC recovery is longer than microfracture alone, and that is intentional: the collagen scaffold needs several months to mature into stable repair tissue before the hip can be loaded normally.

The four phases run roughly as follows:

• Weeks 1–4: The hip is kept non-weight-bearing; crutches are required throughout this period to protect the graft while the stem-cell-rich clot stabilises within the membrane.
• Weeks 4–7: Partial loading begins, guided by physiotherapy. Gentle cycling and pool-based movement are typically introduced during this window.
• Month 2–6: Most patients return to daily activities and light or sedentary work. Higher-demand roles — those requiring prolonged standing or manual handling — may need longer.
• Month 12 and beyond: Structured return to sport and high-impact activity, once the repair tissue has had time to consolidate.

Physiotherapy runs through every phase. Early passive range-of-motion exercises help prevent stiffness while loading is restricted; later sessions shift towards progressive strengthening. The treating team ordinarily coordinates physiotherapy referral — specific exercises and milestones are tailored to each patient at that stage.

Accessing AMIC in Lincolnshire and the wider non-London catchment

Specialist hip cartilage assessment — including AMIC — is available to patients in Lincolnshire and the wider non-London catchment without travelling to a London centre. Lincolnshire Hip is part of the MSK Doctors group, with clinics in Sleaford and Grantham, and accepts patients without a GP referral for hip assessment.

An initial consultation typically involves a clinical history and physical examination, followed by MRI to characterise lesion grade and size, and plain X-rays to establish the Tönnis background osteoarthritis grade. Together, these establish whether the lesion falls within the eligibility profile described in the preceding sections — focal, full-thickness, without advanced joint-space loss.

At a national level, the REPAIR pilot RCT (discussed in the evidence section above) confirms that AMIC is now being evaluated in formal NHS-registered pathways — providing a clear signal of the procedure's standing within UK specialist practice.

For patients who have been told to wait, or who have been offered only microfracture, an independent specialist assessment at this stage can clarify whether scaffold-augmented cartilage repair remains a realistic option before the hip deteriorates to the point where preservation surgery is no longer appropriate.

1. [1] Outcomes of Arthroscopic Joint Preservation Techniques for Chondral Lesions of the Hip: An Updated Systematic Review. (2023). https://doi.org/10.1016/j.arthro.2023.11.019 https://doi.org/10.1016/j.arthro.2023.11.019
2. [2] Arthroscopic treatment of chondral defects in the hip: AMIC, MACI, MATT and other options. (2017). https://doi.org/10.1051/sicotj/2017029 https://doi.org/10.1051/sicotj/2017029
3. [3] Autologous Membrane Induced Chondrogenesis (AMIC) for the treatment of acetabular chondral defect. (2016). https://doi.org/10.11138/mltj/2016.6.3.367 https://doi.org/10.11138/mltj/2016.6.3.367
4. [4] Outcomes of autologous chondrocyte transplantation (ACT) and autologous matrix-induced chondrogenesis (AMIC) in the hip: a systematic review and meta-analysis. (2025). https://doi.org/10.1186/s13018-025-05862-5 https://doi.org/10.1186/s13018-025-05862-5
5. [5] Autologous Matrix-Induced Chondrogenesis for the Treatment of Hip Acetabular Chondral Lesions Demonstrates Improved Outcomes: A Systematic Review. (2024). https://doi.org/10.1016/j.arthro.2024.04.028 https://doi.org/10.1016/j.arthro.2024.04.028
6. [6] Mid-term results of AMIC used for large chondral defects in femoroacetabular impingement hips. (2023). https://doi.org/10.1302/1358-992x.2023.12.029 https://doi.org/10.1302/1358-992x.2023.12.029